A multicenter study of attitudinal barriers to cancer pain management
- 629 Downloads
The purpose of this study was to examine attitudinal barriers to cancer pain management and their relationship to pain, analgesic use, clinical, and demographic variables, as well as QOL, in a large sample of patients receiving strong opioids for pain in three European countries.
Participants in the present study were 555 patients with cancer, 18 years and older recruited from six centers in Germany, Iceland, and Norway. All had received strong opioids for at least 72 h. Data was collected with the Barriers Questionnaire-II, the Brief Pain Inventory, and the European Organization for Research and Treatment of Cancer QLQ-C30.
The mean (SD) age of patients was 61.68 (12.35) years and 53% were men. Most common diagnoses were gastrointestinal, lung, prostate, and breast cancer. The mean (SD) time from diagnosis was 32.24 (44.55) and 4.97 (9.64) months from start of opioid therapy. Mean (SD) pain severity was 3.19 (1.93) on a 0 to 10 scale, and 46.5% reported worst pain of 7 or higher. Attitudinal barriers had a mean (SD) of 1.95 (0.82) on a 0–5 scale, with fear of addiction as the strongest barrier across countries 2.85 (1.49). Barrier scores increased with age, and were higher among men than women. Higher barrier scores were associated with higher pain severity and interference, and lower performance status, but not with global health-QOL. Patients who had been on opioids for a shorter time reported higher barriers.
Attitudinal barriers are frequent in cancer pain patients on opioids and are associated with less effective pain control.
KeywordsBarriers Cancer Pain Analgesics International Multicenter
We would like to acknowledge Gudbjorg J Gudlaugsdottir and Gunnhild Jakobsen for their contribution to data collection and management and Dr. Sandra Ward for her helpful insight and expertise when preparing this manuscript.
PK was the principal investigator on the large parent study and responsible for the study protocol. All authors were responsible for data collection at their centers. SG was responsible for data analysis and writing the manuscript, SG and VS prepared the original manuscript, and all authors discussed the results and commented on the manuscript.
Compliance with ethical standards
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. All participant received information about study participation and their rights and provided informed consent.
Conflict of interest
PK has received lecture honorarium from Mundipharma. The authors have full control of all primary data and agree to allow the journal to review the data if requested.
This study was funded by the European Palliative Care Research Collaborative, 6th EU program, Landspitali—the National University Hospital of Iceland Research Fund, University of Iceland Research Fund, the Icelandic Nurses Association Research Fund, the Icelandic Cancer Society Research Fund, the Memorial fund of the Palliative Care at Landspitali—the National University Hospital of Iceland, the Scientific fund of the Oncology Department at Landspitali—the National University Hospital of Iceland, and Bergthora Magnusdottir and Jakob J Bjarnason Memorial Fund.
- 10.Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JCJM, Kaasa S, Klee MC, Osoba D, Razavi D, Rofe PB, Schraub S, Sneeuw KCA, Sullivan M, Takeda F (1993) The European organisation for research and treatment of cancer QLQ-C30: A quality-of-lifeinstrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:365–376Google Scholar
- 16.Klepstad P, Fladvad T, Skorpen F, Bjordal K, Caraceni A, Dale O, Davies A, Kloke M, Lundstrom S, Maltoni M, Radbruch L, Sabatowski R, Sigurdardottir V, Strasser F, Fayers PM, Kaasa S, European Palliative Care Research C, European Association for Palliative Care Research N (2011) Influence from genetic variability on opioid use for cancer pain: a European genetic association study of 2294 cancer pain patients. Pain 152:1139–1145CrossRefPubMedGoogle Scholar
- 18.Kwon JH, Oh SY, Chisholm G, Lee JA, Lee JJ, Park KW, Nam SH, Song HH, Lee K, Zang DY, Kim HY, Choi DR, Kim HJ, Kim JH, Jung JY, Jang G, Kim HS, Won JY, Bruera E (2013) Predictors of high score patient-reported barriers to controlling cancer pain: a preliminary report. Support Care Cancer 21:1175–1183CrossRefPubMedGoogle Scholar
- 25.Pasternak GW (2001) The pharmacology of mu analgesics: from patients to genes. Neuroscientist Rev J Bringing Neurobiol Neurol Psychiatry 7:220–231Google Scholar